Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma

BACKGROUND: The purpose of this study was to quantitatively evaluate the tumor accumulation and heterogeneity of (111)In-ibritumomab tiuxetan (Zevalin®) and tumor accumulation of (18)F-fluoro-deoxyglucose (FDG) and compare them to the tumor response in B-cell non-Hodgkin’s lymphoma patients receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanaoka, Kohei, Hosono, Makoto, Tatsumi, Yoichi, Ishii, Kazunari, Im, Sung-Woon, Tsuchiya, Norio, Sakaguchi, Kenta, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385239/
https://www.ncbi.nlm.nih.gov/pubmed/25853016
http://dx.doi.org/10.1186/s13550-015-0093-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385239/
https://www.ncbi.nlm.nih.gov/pubmed/25853016
http://dx.doi.org/10.1186/s13550-015-0093-3

Ejemplares similares